Psychedelics and Addiction: The Surprising Research on Breaking Substance Use Cycles

# Psychedelics and Addiction: The Surprising Research on Breaking Substance Use Cycles

Using one psychoactive substance to treat addiction to another sounds paradoxical — until you look at the data. Some of the most compelling research in the entire psychedelic medicine field involves treating addiction, and the results are challenging long-held assumptions about how substance use disorders work and what it takes to break them.

Psilocybin for alcohol use disorder

A [landmark 2022 randomized clinical trial by Bogenschutz and colleagues in JAMA Psychiatry](https://pubmed.ncbi.nlm.nih.gov/36001306/) assigned 95 adults with alcohol use disorder (93 in the primary analysis) to two day-long medication sessions of psilocybin or diphenhydramine (active placebo) plus 12 weeks of manualized motivational and cognitive-behavioral psychotherapy.

The primary outcome — percentage of heavy drinking days over the 32-week double-blind period — was significantly lower in the psilocybin arm (9.7%) than in the diphenhydramine arm (23.6%), a 13.9-percentage-point absolute difference (95% CI 3.0-24.7, p=0.01). Mean daily alcohol consumption was also lower in the psilocybin group, with no serious adverse events.

Psilocybin for tobacco addiction

An earlier study from Johns Hopkins gave psilocybin-assisted therapy to 15 long-term smokers who had failed multiple quit attempts. At six months, 80% were confirmed abstinent — a quit rate that dwarfs the 25-35% typical of the best available smoking cessation treatments.

A larger randomized trial is underway and not yet completed, so the 80% figure should be interpreted with caution given the small sample size. But even if the effect is half as large in a bigger trial, it would represent a meaningful advance.

Ibogaine for opioid withdrawal

Ibogaine — derived from the root bark of the African iboga plant — has attracted attention for its apparent ability to reduce opioid withdrawal symptoms and cravings. Unlike other psychedelics, ibogaine seems to have specific pharmacological effects on the opioid system.

A 2024 observational study of military veterans treated with ibogaine in Mexico (it's not legal in the US) found significant reductions in PTSD symptoms, depression, and anxiety that persisted at one month follow-up.

However, ibogaine carries a real safety risk — it can cause dangerous cardiac arrhythmias, and several deaths have been attributed to its use. This cardiac toxicity makes ibogaine unlikely to receive FDA approval in its current form, though synthetic derivatives with better safety profiles are being developed.

Ketamine for cocaine and alcohol dependence

Ketamine is being studied for multiple addictions with promising early results. A 2022 study found that ketamine combined with mindfulness-based relapse prevention helped people with alcohol use disorder maintain sobriety longer than either intervention alone.

For cocaine dependence — a condition with no FDA-approved medications — ketamine has shown intriguing results in small trials, reducing cravings and prolonging abstinence.

Why psychedelics might work for addiction

The leading theory involves something researchers call the "mystical experience" or "ego dissolution." During a high-dose psychedelic session, many people report a profound sense of interconnectedness, a dissolution of their usual sense of self, and a shift in their relationship to the substance they've been dependent on.

In the psilocybin-for-alcohol study, the intensity of the mystical experience during the session correlated with drinking outcomes — participants who had more profound experiences reduced their drinking more.

This doesn't mean you need a mystical experience to recover from addiction. But it suggests that psychedelics may be facilitating a fundamental shift in perspective that other treatments can't easily replicate — a kind of psychological reset that helps people break out of deeply entrenched patterns.

At the neurobiological level, psychedelics promote rapid neuroplasticity — the formation of new neural connections. Addiction involves deeply grooved neural pathways that drive compulsive behavior. Psychedelics may help create new pathways that offer alternatives to the addictive loop.

The paradox of using drugs to treat drug addiction

This concern comes up constantly, and it deserves a serious answer.

Psychedelics are generally not addictive in the pharmacological sense. They don't produce the dopamine-driven reinforcement cycle that characterizes substances of abuse. Tolerance develops rapidly (within days), making daily use impractical. Most people who use psychedelics therapeutically describe the experience as meaningful but not something they're eager to repeat frequently.

That said, any substance that alters consciousness should be used carefully, especially in people with addiction histories. The clinical trial protocols are extremely structured for a reason.

Where this research is going

Multiple large-scale trials are underway or planned for psilocybin in alcohol use disorder and tobacco dependence. The FDA has granted "breakthrough therapy" designation to psilocybin for treatment-resistant depression, which could accelerate the regulatory pathway for other indications including addiction.

If these results hold up in larger trials, psychedelic-assisted therapy could become one of the most significant additions to addiction medicine in decades — particularly for conditions like alcohol use disorder and tobacco dependence where existing treatments have modest success rates.

---

This article is for educational purposes. Dr. Kim does not currently offer psychedelic-assisted therapy for addiction. If you're struggling with substance use, evidence-based treatment is available. [Talk to us](/intake/mental-health).